AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Endo pharmaceuticals lidoderm11/9/2023 ![]() This press release includes statements that constitute "forward-looking statements," including with regard to sales of products and the company's strategy, future growth and performance. Our workforce of approximately 30,000 people is dedicated to creating better health for a better world, one person at a time. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in about 145 countries and territories. ![]() In addition, we offer a wide range of antiretroviral therapies, upon which nearly 50% of HIV/AIDS patients in developing countries depend. We offer a growing portfolio of around 1,400 generic pharmaceuticals and several brand medications. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs make reliability and service excellence a habit do what's right, not what's easy and impact the future through passionate global leadership. Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Fifty of these pending ANDAs are potential first-to-file opportunities, representing $33.4 billion in annual brand sales, for the 12 months ending December 31, 2014, according to IMS Health. sales of approximately $1.1 billion for the 12 months ending June 30, 2015, according to IMS Health.Ĭurrently, Mylan has 266 ANDAs pending FDA approval representing $100 billion in annual brand sales, according to IMS Health. We look forward to continue innovating to meet unmet needs as we deliver on our promise to bring complex, difficult-to-manufacture products to market to benefit patients, providers and payors in the U.S. Mylan's presentation of this product comes in the form of a thin, lightweight patch, and offers patients a high quality, affordable treatment option within the pain management space. Mylan CEO Heather Bresch said: "We are very pleased to launch our Lidocaine Patch 5%. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for relief of pain associated with post-herpetic neuralgia. Mylan received final approval from the U.S. launch of its Lidocaine Patch 5%, which is the generic version of Endo Pharmaceutical's Lidoderm ®. HERTFORDSHIRE, England and PITTSBURGH, Aug.
0 Comments
Read More
Leave a Reply. |